Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis - PubMed

Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis

Rina Aharoni et al. Inflamm Bowel Dis. 2005 Feb.

Abstract

Inflammatory bowel diseases are characterized by detrimental immune reactivity in the gut and imbalance between proinflammatory and antiinflammatory reactivity. In an attempt to downregulate inflammatory bowel disease, we tested whether the immunomodulator glatiramer acetate (GA; Copaxone, copolymer 1), an approved drug for the treatment of multiple sclerosis, can ameliorate trinitrobenzene sulfonic acid (TNBS)-induced colitis, a murine model that resembles human Crohn's disease. Experimental colitis was induced by rectal instillation of TNBS in 3 mice strains: BALB/c, SJL/J, and (SJL/JXBALB/c)F1, and its severity was evaluated by gross colon injury, histologic damage, body weight, and survival rate. We studied the effect of GA on all these parameters as well as on lymphocyte reactivity manifested by proliferation and secretion of tumor necrosis factor-alpha, and transforming growth factor-beta. GA treatment significantly suppressed the various manifestations of TNBS-induced colitis as demonstrated by substantial reduction in the macroscopic colonic damage, preservation of the microscopic colonic structure, reduced weight loss, and improved long-term survival, in GA treated mice compared with untreated mice. The parenteral route was more effective than the oral route. GA suppressed the proliferation of local mesenteric lymphocytes to syngeneic colon extract and the detrimental tumor necrosis factor-alpha secretion. In addition, it induced a beneficial secretion of transforming growth factor-beta. The ability of GA to effectively modulate the clinical manifestations and the detrimental immune response involved in experimental colitis warrants further studies to determine the clinical efficacy of GA in the treatment of human inflammatory bowel diseases.

Similar articles

• Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis.

  Silva I, Pinto R, Mateus V. Silva I, et al. J Clin Med. 2019 Oct 1;8(10):1574. doi: 10.3390/jcm8101574. J Clin Med. 2019. PMID: 31581545 Free PMC article. Review.

• Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.

  Aharoni R, Kayhan B, Brenner O, Domev H, Labunskay G, Arnon R. Aharoni R, et al. J Pharmacol Exp Ther. 2006 Jul;318(1):68-78. doi: 10.1124/jpet.106.103192. Epub 2006 Apr 19. J Pharmacol Exp Ther. 2006. PMID: 16624971

• Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.

  Arnon R, Aharoni R. Arnon R, et al. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14593-8. doi: 10.1073/pnas.0404887101. Epub 2004 Sep 15. Proc Natl Acad Sci U S A. 2004. PMID: 15371592 Free PMC article.

• The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.

  Aharoni R, Sonego H, Brenner O, Eilam R, Arnon R. Aharoni R, et al. Immunol Lett. 2007 Oct 15;112(2):110-9. doi: 10.1016/j.imlet.2007.07.009. Epub 2007 Aug 8. Immunol Lett. 2007. PMID: 17719654

• TNBS-colitis.

  Neurath M, Fuss I, Strober W. Neurath M, et al. Int Rev Immunol. 2000;19(1):51-62. doi: 10.3109/08830180009048389. Int Rev Immunol. 2000. PMID: 10723677 Review.

Cited by

• The Evolving Mechanisms of Action of Glatiramer Acetate.

  Prod'homme T, Zamvil SS. Prod'homme T, et al. Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a029249. doi: 10.1101/cshperspect.a029249. Cold Spring Harb Perspect Med. 2019. PMID: 29440323 Free PMC article. Review.

• Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

  Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS. Lalive PH, et al. CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. CNS Drugs. 2011. PMID: 21476611 Free PMC article. Review.

• The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics.

  Camara-Lemarroy CR, Metz L, Meddings JB, Sharkey KA, Wee Yong V. Camara-Lemarroy CR, et al. Brain. 2018 Jul 1;141(7):1900-1916. doi: 10.1093/brain/awy131. Brain. 2018. PMID: 29860380 Free PMC article. Review.

• Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis.

  Silva I, Pinto R, Mateus V. Silva I, et al. J Clin Med. 2019 Oct 1;8(10):1574. doi: 10.3390/jcm8101574. J Clin Med. 2019. PMID: 31581545 Free PMC article. Review.

• The effect of dexmedetomidine on inflammatory response of septic rats.

  Zhang J, Wang Z, Wang Y, Zhou G, Li H. Zhang J, et al. BMC Anesthesiol. 2015 May 1;15:68. doi: 10.1186/s12871-015-0042-8. BMC Anesthesiol. 2015. PMID: 25929655 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information